These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 38218180)
1. Structural insight into CD93 recognition by IGFBP7. Xu Y; Sun Y; Zhu Y; Song G Structure; 2024 Mar; 32(3):282-291.e4. PubMed ID: 38218180 [TBL] [Abstract][Full Text] [Related]
2. Structural insight into CD93 recognition by IGFBP7. Xu Y; Sun Y; Zhu Y; Song G bioRxiv; 2023 Jun; ():. PubMed ID: 37333140 [TBL] [Abstract][Full Text] [Related]
3. Blockade of the CD93 pathway normalizes tumor vasculature to facilitate drug delivery and immunotherapy. Sun Y; Chen W; Torphy RJ; Yao S; Zhu G; Lin R; Lugano R; Miller EN; Fujiwara Y; Bian L; Zheng L; Anand S; Gao F; Zhang W; Ferrara SE; Goodspeed AE; Dimberg A; Wang XJ; Edil BH; Barnett CC; Schulick RD; Chen L; Zhu Y Sci Transl Med; 2021 Jul; 13(604):. PubMed ID: 34321321 [TBL] [Abstract][Full Text] [Related]
4. CD93 promotes β1 integrin activation and fibronectin fibrillogenesis during tumor angiogenesis. Lugano R; Vemuri K; Yu D; Bergqvist M; Smits A; Essand M; Johansson S; Dejana E; Dimberg A J Clin Invest; 2018 Aug; 128(8):3280-3297. PubMed ID: 29763414 [TBL] [Abstract][Full Text] [Related]
5. Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization. Li Y; Fu L; Wu B; Guo X; Shi Y; Lv C; Yu Y; Zhang Y; Liang Z; Zhong C; Han S; Xu F; Tian Y Cancer Cell Int; 2023 Sep; 23(1):189. PubMed ID: 37660019 [TBL] [Abstract][Full Text] [Related]
6. The small GTPase Rab5c is a key regulator of trafficking of the CD93/Multimerin-2/β1 integrin complex in endothelial cell adhesion and migration. Barbera S; Nardi F; Elia I; Realini G; Lugano R; Santucci A; Tosi GM; Dimberg A; Galvagni F; Orlandini M Cell Commun Signal; 2019 May; 17(1):55. PubMed ID: 31138217 [TBL] [Abstract][Full Text] [Related]
7. Dissecting the CD93-Multimerin 2 interaction involved in cell adhesion and migration of the activated endothelium. Galvagni F; Nardi F; Spiga O; Trezza A; Tarticchio G; Pellicani R; Andreuzzi E; Caldi E; Toti P; Tosi GM; Santucci A; Iozzo RV; Mongiat M; Orlandini M Matrix Biol; 2017 Dec; 64():112-127. PubMed ID: 28912033 [TBL] [Abstract][Full Text] [Related]
8. Elevated expression of the C-type lectin CD93 in the glioblastoma vasculature regulates cytoskeletal rearrangements that enhance vessel function and reduce host survival. Langenkamp E; Zhang L; Lugano R; Huang H; Elhassan TE; Georganaki M; Bazzar W; Lööf J; Trendelenburg G; Essand M; Pontén F; Smits A; Dimberg A Cancer Res; 2015 Nov; 75(21):4504-16. PubMed ID: 26363010 [TBL] [Abstract][Full Text] [Related]
9. Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface. Khan KA; Naylor AJ; Khan A; Noy PJ; Mambretti M; Lodhia P; Athwal J; Korzystka A; Buckley CD; Willcox BE; Mohammed F; Bicknell R Oncogene; 2017 Nov; 36(44):6097-6108. PubMed ID: 28671670 [TBL] [Abstract][Full Text] [Related]
10. CD93 and dystroglycan cooperation in human endothelial cell adhesion and migration adhesion and migration. Galvagni F; Nardi F; Maida M; Bernardini G; Vannuccini S; Petraglia F; Santucci A; Orlandini M Oncotarget; 2016 Mar; 7(9):10090-103. PubMed ID: 26848865 [TBL] [Abstract][Full Text] [Related]
11. The Binding of CD93 to Multimerin-2 Promotes Choroidal Neovascularization. Tosi GM; Neri G; Barbera S; Mundo L; Parolini B; Lazzi S; Lugano R; Poletto E; Leoncini L; Pertile G; Mongiat M; Dimberg A; Galvagni F; Orlandini M Invest Ophthalmol Vis Sci; 2020 Jul; 61(8):30. PubMed ID: 32697305 [TBL] [Abstract][Full Text] [Related]
12. Identify the immune characteristics and immunotherapy value of CD93 in the pan-cancer based on the public data sets. Guo A; Zhang J; Tian Y; Peng Y; Luo P; Zhang J; Liu Z; Wu W; Zhang H; Cheng Q Front Immunol; 2022; 13():907182. PubMed ID: 36389798 [TBL] [Abstract][Full Text] [Related]
13. CD93 a potential player in cytotrophoblast and endothelial cell migration. Fantone S; Tossetta G; Di Simone N; Tersigni C; Scambia G; Marcheggiani F; Giannubilo SR; Marzioni D Cell Tissue Res; 2022 Jan; 387(1):123-130. PubMed ID: 34674045 [TBL] [Abstract][Full Text] [Related]
14. CD93 interacts with the PDZ domain-containing adaptor protein GIPC: implications in the modulation of phagocytosis. Bohlson SS; Zhang M; Ortiz CE; Tenner AJ J Leukoc Biol; 2005 Jan; 77(1):80-9. PubMed ID: 15459234 [TBL] [Abstract][Full Text] [Related]
15. Elevated expression of CD93 promotes angiogenesis and tumor growth in nasopharyngeal carcinoma. Bao L; Tang M; Zhang Q; You B; Shan Y; Shi S; Li L; Hu S; You Y Biochem Biophys Res Commun; 2016 Aug; 476(4):467-474. PubMed ID: 27255994 [TBL] [Abstract][Full Text] [Related]
17. The epidermal growth factor-like domain of CD93 is a potent angiogenic factor. Kao YC; Jiang SJ; Pan WA; Wang KC; Chen PK; Wei HJ; Chen WS; Chang BI; Shi GY; Wu HL PLoS One; 2012; 7(12):e51647. PubMed ID: 23272129 [TBL] [Abstract][Full Text] [Related]
18. Modulated interaction of the ERM protein, moesin, with CD93. Zhang M; Bohlson SS; Dy M; Tenner AJ Immunology; 2005 May; 115(1):63-73. PubMed ID: 15819698 [TBL] [Abstract][Full Text] [Related]
19. CD93 is rapidly shed from the surface of human myeloid cells and the soluble form is detected in human plasma. Bohlson SS; Silva R; Fonseca MI; Tenner AJ J Immunol; 2005 Jul; 175(2):1239-47. PubMed ID: 16002728 [TBL] [Abstract][Full Text] [Related]
20. CD93 regulates breast cancer growth and vasculogenic mimicry through the PI3K/AKT/SP2 signaling pathway activated by integrin β1. Liu H; Zhang J; Zhao Y; Fan Z; Yang Y; Mao Y; Yang J; Ma S J Biochem Mol Toxicol; 2024 Apr; 38(4):e23688. PubMed ID: 38511888 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]